Connect to other sites within the UBM Medica Network
Cancer Screening Often Excessive in Older Patients
Patients with limited life expectancies often undergo routine cancer screenings despite evidence that they are unlikely to benefit and may experience harm.
Test Could Detect HPV-Related Head and Neck Cancer Recurrence
Researchers have developed a preliminary test using blood and saliva samples to detect disease recurrence in patients with HPV-related head and neck cancer.
Best to Stage Esophageal Cancer After Neoadjuvant Chemo
The stage of esophageal adenocarcinomas after neoadjuvant chemotherapy is predictive of outcomes, rather than the stage determined prior to therapy.
Mutation in Cutaneous Lymphoma Linked to Poor Prognosis
A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.
Best Methods for ALK Screening in Non–Small-Cell Lung Cancer
A new study sheds light on the prevalence of ALK positive non–small-cell lung cancer and suggests the best methods for screening.
FDA Approves Avastin for Advanced Cervical Cancer
The US Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of patients with recurrent or metastatic cervical cancer.
Treatment Without Consent?
A delirious head and neck cancer patient does not have the capacity to make treatment decisions. Can we begin palliative radiation therapy without his consent?
New R-CHOP Regimen Promising in DLBCL Subtype
Phase II study results show that a new combination of drugs known as R2CHOP had promising efficacy in the treatment of relapsed diffuse large B-cell lymphoma.
Aspirin May Benefit Obese Breast Cancer Patients
Overweight and obese women with estrogen receptor (ER)-positive breast cancer may benefit from daily non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin.
ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.